Sanofi India Q2 Results 2026: PAT ₹117 Cr +54%, Revenue ₹492 Cr
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
- Revenue
- ₹492Cr
- +3.6% YoY
- Net profit
- ₹117Cr
- +53.9% YoY
- Margin
- 33%
- +5 pp YoY
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Sanofi India Ltd Q2 FY27 key numbers
- Revenue
- Revenue from Operations for Q3 2026 was ₹4,917 million, compared to ₹4,754 million in Q3 2025.
As stated in Sanofi India Ltd's Q2 FY27 results statement · published 30 Oct 2026. Reported figures, not investment advice.
Based on Sanofi India Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Domestic net sales grew by +2% in Q3 2026 compared to Q3 2025. However, profit before exceptional item and tax (proxy for operating profit) is ₹1,577 million, up from ₹1,296 million in Q3 2025, showing an increase of about 22%.
From Sanofi India Ltd's Q2 FY27 earnings-call transcript · updated 30 Oct 2026.
How did Sanofi India's revenue grow in the September 2026 quarter?
- Domestic net sales grew by +2% in Q3 2026 compared to Q3 2025.
- Total net sales increased by 4% in Q3 2026 versus Q3 2025.
- Revenue from Operations for Q3 2026 was ₹4,917 million, compared to ₹4,754 million in Q3 2025.
- Insulin portfolio delivered a 9% growth in Q3 2026 year-on-year.
- Diabetes Injectable segment holds a 55% market share with 14% growth YTD 2026.
2 more points from Sanofi India Ltd's call on revenue
Create a free account to keep reading this call
What happened to Sanofi India's margins in Q2 FY27?
See what Sanofi India Ltd said on profitability & margins — free account, 30 seconds.
What capex is Sanofi India planning?
See what Sanofi India Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Sanofi India raising money or cutting debt?
See what Sanofi India Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Sanofi India's order book?
See what Sanofi India Ltd said on order book & pipeline — free account, 30 seconds.
Sanofi India Ltd — Quarterly revenue & net profit
Sanofi India Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| Revenue | 492 | 475 | +3.6% | 438 | +12.3% |
| Operating profit (EBITDA) | 161 | 134 | +20.1% | 115 | +40% |
| Operating margin | 33% | 28% | +5 pp | 26% | +7 pp |
| Profit before tax | 158 | 102 | +54.9% | 112 | +41.1% |
| Net profit (PAT) | 117 | 76 | +53.9% | 84 | +39.3% |
| EPS (₹) | 50.74 | 33.04 | +53.6% | 36.30 | +39.8% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹492 Cr, net profit ₹117 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →More Q2 FY27 results in Pharmaceuticals & Biotechnology
- Sun Pharmaceutical Industries Q2 FY27 results
- Divis Laboratories Q2 FY27 resultsRevenue ₹3770 Cr · PAT ₹1,127 Cr
- Torrent Pharmaceuticals Q2 FY27 results
- Laurus Labs Q2 FY27 results
- Zydus Lifesciences Q2 FY27 results
- Dr Reddy's Labs Q2 FY27 resultsCapex ₹186 Cr
- Cipla Q2 FY27 results
- Mankind Pharma Q2 FY27 results
All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings
Continue your research
What Sanofi India's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Divis Laboratories (Q2 FY27)
Consolidated total income: ₹3770 crores . Key results statement takeaways from Divis Laboratories Ltd's Q2 FY27 results statement — and how it ranks against sec
- Infinium Pharma (Q2 FY27)
3,940.98 Lacs (about 54.3% increase) . Key results statement takeaways from Infinium Pharmachem Ltd's Q2 FY27 results statement — and how it ranks against secto
- Walpar Nutrition (Q2 FY27)
3,631.14 Lakhs for the half year ended September 30, 2025, reflecting a year-on-year increase of approximately 13.79%. Key results statement takeaways from Walp
- Kilitch Drugs (Q2 FY27)
14.3%) . Key results statement takeaways from Kilitch Drugs (India) Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Sanofi India Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sanofi India Ltd Q2 FY27 results?
Domestic net sales grew by +2% in Q3 2026 compared to Q3 2025. However, profit before exceptional item and tax (proxy for operating profit) is ₹1,577 million, up from ₹1,296 million in Q3 2025, showing an increase of about 22%.
What is Sanofi India Ltd share price analysis?
Sanofi India Ltd currently shows a neutral. The stock trades at a P/E of 21.4 with a market cap of ₹7,346 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Sanofi India Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.